Rafael Blasini, MD
Internal Medicine · Tampa, FLNPI 1942239611
Payments from drug & device makers
Across 513 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AstraZeneca$952
- AbbVie$721
- Pfizer$633
- Bayer$335
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,72399%
- Education$1061%
- Entertainment$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 166 | $2,238 |
| Lilly USA, LLC | 65 | $1,087 |
| AstraZeneca | 62 | $952 |
| AbbVie(2 entities) | 32 | $721 |
| Pfizer | 43 | $633 |
| Bayer | 14 | $335 |
| Sanofi-aventis U.S. LLC | 6 | $328 |
| Astellas Pharma US Inc | 10 | $302 |
| Esperion Therapeutics, Inc. | 7 | $246 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $238 |
| Johnson & Johnson(2 entities) | 14 | $233 |
| Medtronic | 2 | $186 |
| Amarin Pharma, Inc. | 9 | $163 |
| Boehringer Ingelheim | 8 | $136 |
| Amgen | 8 | $130 |
| Abbott | 5 | $114 |
| GSK | 6 | $97 |
| Kowa Pharmaceuticals America, Inc. | 5 | $80 |
| Novartis | 5 | $79 |
| Exact Sciences | 4 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $58 |
| Arbor Pharmaceuticals, Inc. | 3 | $53 |
| Xeris Pharmaceuticals, Inc. | 3 | $47 |
| Merck | 3 | $43 |
| Intuitive Surgical | 1 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Nevro Corp. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Optos, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reveal LINQ$169
- NEXLIZET$125
- NEXLETOL$125
- SOLIQUA 100/33$111
- Ozempic$103
How this compares
$8,843 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $114,668 |
| MounjaroTirzepatide | 49 | $55,805 |
| JardianceEmpagliflozin | 51 | $54,561 |
| EliquisApixaban | 39 | $46,440 |
| FarxigaDapagliflozin Propanediol | 36 | $26,458 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 24 | $24,508 |
| TrulicityDulaglutide | 11 | $19,647 |
| VascepaIcosapent Ethyl | 19 | $19,332 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $5,885 |
| Rosuvastatin Calcium | 491 | $5,835 |
| Telmisartan-AmlodipineTelmisartan/Amlodipine | 15 | $3,778 |
| Atorvastatin Calcium | 391 | $3,273 |
| Telmisartan | 65 | $3,099 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $3,087 |
| Amlodipine Besylate | 521 | $3,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,238 | $114,66898 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $136 | $79,06975 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,087 | $75,45360 claims |
| PfizerEliquis, Paxlovid | $633 | $47,86964 claims |
| AstraZenecaFarxiga | $952 | $26,45836 claims |
| AbbVieSynthroid | $721 | $1,13928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Tampa
- Jhanelle GrayTampa$20.8M
- Sady AlpizarTampa$13.5M
- Karon LociceroTampa$6.6M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.